Salarius Pharmaceuticals' Unattributed - III Round

Salarius Pharmaceuticals raised a round of funding on April 04, 2016.

Salarius Pharmaceuticals is an oncology company developing inhibitors of LSD1 (Lysine-Specific Demethylase). Salarius' lead compound, SP-2577, is moving into clinical development for the treatment of …

Articles about Salarius Pharmaceuticals' Unattributed - III Round: